Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives? - Wikidata - wikimedia - TriplyDB

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

http://www.wikidata.org/entity/Q33586708

about

Inhibition of angiotensin II-induced cardiac hypertrophy and associated ventricular arrhythmias by a p21 activated kinase 1 bioactive peptide.Evidence for distinct effects of exercise in different cardiac hypertrophic disorders.Factors Contributing to Development and Reversal of LVH: A Pilot Study.Is hepatic steatosis associated with left ventricular mass index increase in the general population?Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities.

P2860

Q33889646-133550AD-780F-45A3-9650-3B983BC57218 Q35117452-87475420-F710-45E9-B984-0910B75B3901 Q37102739-064819A4-13EB-437C-8CF8-8FCE1E6963AD Q38663332-4F0CE80D-CD1E-4A1B-8031-A963212ADE9F Q48129928-6D5CF801-6084-4F69-A1BA-16D81AAD4144

P2860

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

http://www.wikidata.org/entity/Q33586708

description

1999 nî lūn-bûn

@nan

1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@ast

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@en

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@nl

type

label

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@ast

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@en

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@nl

prefLabel

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@ast

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@en

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@nl

P1433

Q33586708-4E91D3BE-C8D3-4559-9AA1-EFEC5E5B6548

P1476

Q33586708-872A2286-9E19-4799-A1A3-C62A041EFF4F

P2093

Q33586708-3EA9D5F0-DA84-4BCB-A269-8F801A1ABF7F

Q33586708-4746DDAC-9DF2-4DD5-A3D7-34DA0575F1E8

Q33586708-F63CF356-DD09-4469-AF88-FE9665BEC865

P2860

Q33586708-04585E66-AC88-4C42-804E-B829E2CB47CA

Q33586708-05BF195C-D4AF-40BF-9296-06C2D5581E92

Q33586708-0B72B3D9-5246-4A45-9799-B98FD33353C4

Q33586708-0CA31207-DE83-4C67-8990-85DB1E531FB0

Q33586708-0F49482E-41F2-4309-B8B2-C559E6F7E524

Q33586708-1546F2B2-E3E1-4BD0-B528-698E9277F4B5

Q33586708-1DFC01A1-79BC-4438-845F-A4A8B593565A

Q33586708-1F2409A0-82DF-4B84-A02B-C2F6A4BF3CC5

Q33586708-2B32830E-7BD4-4102-873B-BC1E19D03AA8

Q33586708-2EDFF6B7-ADE5-49C8-BC4E-A28A58B7E346

P304

Q33586708-B72A9A58-07EF-4814-AC49-D8D6E001BE61

P31

Q33586708-5F42C339-AD25-4AA3-90D9-FC4C29F66A15

P356

Q33586708-4332D58F-6757-48C4-8B62-C2D75137D539

P407

Q33586708-A73E8ED5-FFBD-48B7-9B41-5B8DBCA0CA98

P433

Q33586708-9271FBF9-F6DC-46DF-BB65-CC11068E8F97

P478

Q33586708-F946DEE9-6A20-410C-985D-F4134F393722

P577

Q33586708-9CA159B4-E9C3-408B-B20D-79BD0E46458C

P5875

Q33586708-0ED5FBC7-ED60-487E-8A17-2387C6B92CD2

P698

Q33586708-08E7CFDA-7023-4D49-A5B0-F21EE985ED29

P932

Q33586708-F75AF044-383F-4788-83FD-676A94276B64

P356

J.1365-2125.1999.00871.X

P1433

British Journal of Clinical Pharmacology

P1476

Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

@en

P2093

D J Sheridan

http://www.w3.org/2001/XMLSchema#string

M P Kingsbury

http://www.w3.org/2001/XMLSchema#string

N A Flores

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype

Blood pressure, stroke, and coronary heart disease

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.

Expression of AT2 receptors in the developing rat fetus.

Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation

Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy.

Investigation of impaired coronary vasodilator reserve in the guinea pig heart with pressure induced hypertrophy.

Abnormalities of the coronary circulation associated with left ventricular hypertrophy.

Myocardial blood flow distribution in concentric left ventricular hypertrophy

P304

125-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2125.1999.00871.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

1999-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13106809

http://www.w3.org/2001/XMLSchema#string

P698

10190646

http://www.w3.org/2001/XMLSchema#string

P932

2014170

http://www.w3.org/2001/XMLSchema#string